Huntington's Disease News and Research RSS Feed - Huntington's Disease News and Research

Huntington's disease (HD) results from genetically programmed degeneration of brain cells, called neurons, in certain areas of the brain. This degeneration causes uncontrolled movements, loss of intellectual faculties, and emotional disturbance. HD is a familial disease, passed from parent to child through a mutation in the normal gene. Each child of an HD parent has a 50-50 chance of inheriting the HD gene. If a child does not inherit the HD gene, he or she will not develop the disease and cannot pass it to subsequent generations. A person who inherits the HD gene will sooner or later develop the disease. Whether one child inherits the gene has no bearing on whether others will or will not inherit the gene. Some early symptoms of HD are mood swings, depression, irritability or trouble driving, learning new things, remembering a fact, or making a decision. As the disease progresses, concentration on intellectual tasks becomes increasingly difficult and the patient may have difficulty feeding himself or herself and swallowing. The rate of disease progression and the age of onset vary from person to person. A genetic test, coupled with a complete medical history and neurological and laboratory tests, helps physicians diagnose HD. Presymptomic testing is available for individuals who are at risk for carrying the HD gene. In 1 to 3 percent of individuals with HD, no family history of HD can be found.
Innovative strategy can reverse symptoms in neurodegenerative diseases

Innovative strategy can reverse symptoms in neurodegenerative diseases

Alzheimer's and Parkinson's disease are the two most common neurodegenerative disorders worldwide and cause untold suffering to millions of patients and their families. Treatments for these diseases are limited, and no cures exist. Now, a new study describes an innovative strategy that reverses symptoms in these neurodegenerative diseases - at least in fruit flies which had been genetically altered to model the diseases. [More]
Scientists discover CD2AP protein that plays key role in nervous system

Scientists discover CD2AP protein that plays key role in nervous system

University of Louisville researchers have discovered that a protein previously known for its role in kidney function also plays a significant role in the nervous system. In an article featured in the April 13 issue of the Journal of Neuroscience, they show that the adaptor protein CD2AP is a key player in a type of neural growth known as collateral sprouting. [More]
Glial cells can modulate specific nerve endings in the brain, find Rockefeller scientists

Glial cells can modulate specific nerve endings in the brain, find Rockefeller scientists

More than half of our brains are made up of glial cells, which wrap around nerve fibers and insulate them--similarly to how the plastic casing of an electric cable insulates the copper wire within--allowing electrical and chemical impulses to travel faster. [More]
Rockefeller scientists study molecular mechanism that causes linker cell death in worms

Rockefeller scientists study molecular mechanism that causes linker cell death in worms

Some cells are meant to live, and some are meant to die. The linker cell of Caenorhabditis elegans, a tiny worm that is a favored model organism for biologists, is among those destined for termination. [More]
Commonly used fungicides could cause gene expression changes in brain cells

Commonly used fungicides could cause gene expression changes in brain cells

Scientists at the UNC School of Medicine have found a class of commonly used fungicides that produce gene expression changes similar to those in people with autism and neurodegenerative conditions, including Alzheimer's disease and Huntington's disease. [More]
Findings offer novel way for creating drugs to stop mitochondria from destroying cells during stress

Findings offer novel way for creating drugs to stop mitochondria from destroying cells during stress

Malfunctioning mitochondria — the power plants in cells — are behind the damage caused by strokes, heart attacks, and neurodegenerative diseases, but little has been known about how to stop these reactors from melting down, destroying cells and tissue. Mitochondria also take up calcium, which regulates energy production. [More]
New drug shows promise against Huntington's disease

New drug shows promise against Huntington's disease

A drug that would be the first to target the cause of Huntington's disease (HD) is effective and safe when tested in mice and monkeys, according to data released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016. [More]
Sangamo presents immunological data from SB-728-T HIV clinical study at CROI 2016

Sangamo presents immunological data from SB-728-T HIV clinical study at CROI 2016

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced the presentation of immunological data from the Company's clinical trials of SB-728-T, a ZFP Therapeutic designed to provide functional control of HIV. [More]
Revealing dynamic protein complexes with NMR: an interview with Elisar Barbar

Revealing dynamic protein complexes with NMR: an interview with Elisar Barbar

In my lab, we focus on understanding structure, assembly and regulation of the LC8 protein interaction network, the array of LC8 interactions with diverse partners which affect multiple cellular functions in biomedical systems. [More]
Synthetic RNA and DNA could reverse protein deficiency that causes Friedreich's ataxia

Synthetic RNA and DNA could reverse protein deficiency that causes Friedreich's ataxia

Researchers at UT Southwestern Medical Center have identified synthetic RNA and DNA that reverses the protein deficiency causing Friedreich's ataxia, a neurological disease for which there is currently no cure. [More]
TSRI scientists receive $1.7 million NIH grant to find new target for treating Huntington's disease

TSRI scientists receive $1.7 million NIH grant to find new target for treating Huntington's disease

Scientists from the Florida campus of The Scripps Research Institute have won nearly $1.7 million from the National Institutes of Health's National Institute of Neurological Disorders and Stroke to investigate the mechanisms that contribute to Huntington's disease, a fatal inherited disease that some have described as having ALS, Parkinson's and Alzheimer's--at the same time. [More]
FDA clears Sangamo BioSciences' SB-318 IND application for treatment of MPS I

FDA clears Sangamo BioSciences' SB-318 IND application for treatment of MPS I

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application for SB-318, a single treatment strategy intended to provide a life-long therapy for Mucopolysaccharidosis Type I (MPS I). [More]
Lamin nucleoskeleton disordered in Alzheimer's

Lamin nucleoskeleton disordered in Alzheimer's

Brain cell death in Alzheimer's disease is linked to disruption of a skeleton that surrounds the nucleus of the cells, a researcher in the School of Medicine at The University of Texas Health Science Center at San Antonio said. [More]
Study finding could shed light on molecular mechanisms underlying Huntington's disease

Study finding could shed light on molecular mechanisms underlying Huntington's disease

Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder. [More]
FDA grants Orphan Drug Designation to Ionis Pharmaceuticals' IONIS-HTT Rx for treatment of HD patients

FDA grants Orphan Drug Designation to Ionis Pharmaceuticals' IONIS-HTT Rx for treatment of HD patients

Ionis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to IONIS-HTTRx for the treatment of patients with Huntington's disease (HD). [More]
Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced the presentation of Phase 2 data from two of the Company's ongoing clinical trials (SB-728-1101 Cohort 3* and SB-728-mR-1401) of SB-728-T, which is being developed for the functional control of HIV/AIDS. [More]
Tetra begins human Phase 1 safety trials of BPN14770

Tetra begins human Phase 1 safety trials of BPN14770

Tetra Discovery Partners today announced that the company has initiated human Phase 1 safety trials of its lead compound BPN14770, which Tetra is developing as a potential treatment to both improve memory and slow the progression of Alzheimer's disease. [More]
Existing compound offers hope for slowing Huntington's disease progression

Existing compound offers hope for slowing Huntington's disease progression

Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms. [More]
UF Health investigators make new discovery about Huntington's disease

UF Health investigators make new discovery about Huntington's disease

University of Florida Health researchers have made a new discovery about Huntington's disease, showing that the gene that causes the fatal disorder makes an unexpected "cocktail" of mutant proteins that accumulate in the brain. [More]
Utah chemists devise new way to detect DNA damage

Utah chemists devise new way to detect DNA damage

University of Utah chemists devised a new way to detect chemical damage to DNA that sometimes leads to genetic mutations responsible for many diseases, including various cancers and neurological disorders. [More]
Advertisement
Advertisement